© 2003 by Oxford University Press
Journal of the National Cancer Institute, Vol. 95, No. 14, 1062-1071,
July 16, 2003
© 2003 Oxford University Press
ARTICLE |
Human Papillomavirus Type 16 and Immune Status in Human Immunodeficiency Virus-Seropositive Women
Affiliations of authors: H. D. Strickler, R. S. Klein, C. Hall, M. Fazzari, A. J. Durante, R. D. Burk, Albert Einstein College of Medicine, Bronx, NY; J. M. Palefsky, University of California, San Francisco; K. V. Shah, D. D. Celentano, S. Gange, Johns Hopkins University, Baltimore, MD; K. Anastos, Lincoln Medical Center, and Albert Einstein College of Medicine, Bronx; H. Minkoff, Maimonides Medical Center, Brooklyn, NY; A. Duerr, Centers for Disease Control and Prevention, Atlanta, GA; L. S. Massad, Southern Illinois University School of Medicine, Springfield; S. Cu-Uvin, Brown University, Providence, RI; M. Bacon, Georgetown University Medical Center, Washington, DC; P. Schuman, Wayne State University, Detroit, MI; A. M. Levine, University of Southern California, Los Angeles; S. Melnick, National Cancer Institute, Bethesda, MD.
Correspondence to: Howard D. Strickler, M.D., M.P.H., Department of Epidemiology and Social Medicine, Albert Einstein College of Medicine, 1300 Morris Park Ave., Belfer #1308, Bronx, NY 10461 (e-mail: Strickle{at}aecom.yu.edu).
Background: Human papillomavirus (HPV) type 16 is etiologically associated with approximately half of all cervical cancers. It is important, therefore, to determine the characteristics that distinguish HPV16 from other HPV types. A preliminary result based on cross-sectional baseline data in the Women’s Interagency Human Immunodeficiency Virus (HIV) Study (WIHS) suggested that the prevalence of HPV16 might have a weaker association with immune status in HIV-seropositive women than that of other HPV types. To address this issue, we examined HPV test results from repeated study visits in the WIHS and from an independent study, the HIV Epidemiology Research Study (HERS). Methods: HIV-seropositive women in the WIHS (n = 2058) and in the HERS (n = 871) were assessed semiannually. HPV DNA was detected in cervicovaginal lavage specimens by using polymerase chain reaction assays. Prevalence ratios were used to compare the prevalence of each HPV type in women with the lowest CD4+ T-cell counts (<200 T cells/mm3) with that of women with the highest CD4+ T-cell counts (
500 T cells/mm3). A summary prevalence ratio for each HPV type (i.e., across visits and studies) was estimated using generalized estimating equations. The association of CD4+ T-cell stratum with type-specific HPV incidence was measured using multivariable Cox regression models. All statistical tests were two-sided. Results: The prevalence ratio for HPV16 was low compared with that of other HPV types at every study visit in both cohorts. The generalized estimating equation summary prevalence ratio for HPV16 (1.25, 95% confidence interval [CI] = 0.97 to 1.62) was the smallest measured, and it was statistically significantly lower than that of all other HPV types combined (P = .01). The association of CD4+ T-cell stratum with HPV16 incidence was also among the smallest measured (hazard ratio = 1.69, 95% CI = 1.01 to 2.81). Conclusions: The prevalent and incident detection of HPV16 is more weakly associated with immune status in HIV-seropositive women than that of other HPV types, suggesting that HPV16 may be better at avoiding the effects of immune surveillance, which could contribute to HPV16’s strong association with cervical cancer.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  N. Garcia-Sierra, E. Martro, E. Castella, M. Llatjos, A. Tarrats, E. Bascunana, R. Diaz, M. Carrasco, G. Sirera, L. Matas, et al. Evaluation of an Array-Based Method for Human Papillomavirus Detection and Genotyping in Comparison with Conventional Methods Used in Cervical Cancer Screening J. Clin. Microbiol., July 1, 2009; 47(7): 2165 - 2169. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Porras, A. C. Rodriguez, A. Hildesheim, R. Herrero, P. Gonzalez, S. Wacholder, R. D. Burk, and M. Schiffman Human Papillomavirus Types by Age in Cervical Cancer Precursors: Predominance of Human Papillomavirus 16 in Young Women Cancer Epidemiol. Biomarkers Prev., March 1, 2009; 18(3): 863 - 865. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Koshiol, L. Lindsay, J. M. Pimenta, C. Poole, D. Jenkins, and J. S. Smith Persistent Human Papillomavirus Infection and Cervical Neoplasia: A Systematic Review and Meta-Analysis Am. J. Epidemiol., July 15, 2008; 168(2): 123 - 137. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Tornesello, M. L. Duraturo, P. Giorgi-Rossi, M. Sansone, R. Piccoli, L. Buonaguro, and F. M. Buonaguro Human papillomavirus (HPV) genotypes and HPV16 variants in human immunodeficiency virus-positive Italian women J. Gen. Virol., June 1, 2008; 89(6): 1380 - 1389. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Safaeian, M. Kiddugavu, P. E. Gravitt, S. J. Gange, J. Ssekasanvu, D. Murokora, M. Sklar, D. Serwadda, M. J. Wawer, K. V. Shah, et al. Determinants of Incidence and Clearance of High-Risk Human Papillomavirus Infections in Rural Rakai, Uganda Cancer Epidemiol. Biomarkers Prev., June 1, 2008; 17(6): 1300 - 1307. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M O Ng'ayo, E Bukusi, A Rowhani-Rahbar, L A Koutsky, Q Feng, Z A Kwena, and K K Holmes Epidemiology of human papillomavirus infection among fishermen along Lake Victoria Shore in the Kisumu District, Kenya Sex Transm Inf, February 1, 2008; 84(1): 62 - 66. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. G. Harris, R. D. Burk, H. Yu, H. Minkoff, L. S. Massad, D. H. Watts, Y. Zhong, S. Gange, R. C. Kaplan, K. Anastos, et al. Insulin-Like Growth Factor Axis and Oncogenic Human Papillomavirus Natural History Cancer Epidemiol. Biomarkers Prev., January 1, 2008; 17(1): 245 - 248. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Garcia-Pineres, A. Hildesheim, R. Herrero, M. Trivett, M. Williams, I. Atmetlla, M. Ramirez, M. Villegas, M. Schiffman, A. C. Rodriguez, et al. Persistent Human Papillomavirus Infection Is Associated with a Generalized Decrease in Immune Responsiveness in Older Women. Cancer Res., November 15, 2006; 66(22): 11070 - 11076. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Palefsky Biology of HPV in HIV Infection Advances in Dental Research, April 1, 2006; 19(1): 99 - 105. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. F. Schlecht, R. D. Burk, J. M. Palefsky, H. Minkoff, X. Xue, L. S. Massad, M. Bacon, A. M. Levine, K. Anastos, S. J. Gange, et al. Variants of human papillomaviruses 16 and 18 and their natural history in human immunodeficiency virus-positive women J. Gen. Virol., October 1, 2005; 86(10): 2709 - 2720. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Bacon, V. von Wyl, C. Alden, G. Sharp, E. Robison, N. Hessol, S. Gange, Y. Barranday, S. Holman, K. Weber, et al. The Women's Interagency HIV Study: an Observational Cohort Brings Clinical Sciences to the Bench Clin. Vaccine Immunol., September 1, 2005; 12(9): 1013 - 1019. [Full Text] [PDF]
|
|
|
|
|
|
G. M. Clifford, R. K. Rana, S. Franceschi, J. S. Smith, G. Gough, and J. M. Pimenta Human Papillomavirus Genotype Distribution in Low-Grade Cervical Lesions: Comparison by Geographic Region and with Cervical Cancer Cancer Epidemiol. Biomarkers Prev., May 1, 2005; 14(5): 1157 - 1164. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. D. Strickler, R. D. Burk, M. Fazzari, K. Anastos, H. Minkoff, L. S. Massad, C. Hall, M. Bacon, A. M. Levine, D. H. Watts, et al. Natural History and Possible Reactivation of Human Papillomavirus in Human Immunodeficiency Virus-Positive Women J Natl Cancer Inst, April 20, 2005; 97(8): 577 - 586. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. G. Harris, R. D. Burk, J. M. Palefsky, L. S. Massad, J. Y. Bang, K. Anastos, H. Minkoff, C. B. Hall, M. C. Bacon, A. M. Levine, et al. Incidence of Cervical Squamous Intraepithelial Lesions Associated With HIV Serostatus, CD4 Cell Counts, and Human Papillomavirus Test Results JAMA, March 23, 2005; 293(12): 1471 - 1476. [Abstract] [Full Text] [PDF]
|
|